Company / Working Capital
Monopar Therapeutics Working Capital History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$137.7M
FY2025
5-year range
$6.9M / $137.7M
FY2021-FY2025
Trend
-
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital changed +1001% YoY in FY2025, a notable deviation from the 3-year average annual change of +354%.
Based on SEC 10-K filings.
$138M in FY2025.
Improved from $7M to $138M over the past 7 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 19.82 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $137.7M | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2019 | $12.5M | +80.8% |
| FY2018 | $6.9M | -21.6% |
| FY2017 | $8.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026